NASH therapies...NAFLD/Nash are diverse conditions with multifactorial etiology so the diseases are caused by different assaults to the liver each need to be addressed therefore drugs with different mechanism of actions together (combination therapy) seems to be the ultimate future treatment for NASH. Interestingly the metabolic pathways causing the indications are more understood and the scientist are now more than ever emphasizing on the metabolic prevention in order to find a cure for the conditions. We know Tesamorelin targeted proteomic and transcriptomic approach can suppress angogenic, fibrogenic and pro inflammatory proteins in the plasma, all play important role in pathogenesis of NAFL/NASH.
“In my opinion, the future of NASH is going to be binding combination therapies, for which we have a foundation of anti-metabolic therapy, coupled with anti-inflammatory or anti-fibrotic therapy, depending on where patients are in the disease spectrum.
Abdelmalek noted that liver directed pharmacotherapy should be reserved for patients with NASH and “significant” fibrosis, and that anti-metabolic therapy will be critical in the treatment of NASH.”
Potential for FDA approval nears for emerging NASH therapies (healio.com) The other issue with epidemic NAFLD is the comorbidities as the excessive fat accumulated in the liver can also spill in the blood, leading to higher levels of triglyceride that is known risk factor for heart disease, and we know Tesamorelin decreases triglyceride accumulation which is one of the reason Dr. Stanley is now running a trial investigating the role of Tesamorlein in improvement of NAFLD associated cardiovascular risks. So to me THTX’s NASH saga is by all means not over!
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk - Full Text View - ClinicalTrials.gov